论文部分内容阅读
多数卵巢癌患者确诊时已属临床晚期,虽然经过理想的肿瘤细胞减灭术及以顺铂为基础的联合化疗,仍有部分患者出现复发、耐药。因此,晚期卵巢癌仍是当前女性生殖系统恶性肿瘤中引起死亡的主要原因。腹腔温热化疗(IPHC)是一项很有希望的治疗措施,为提高晚期、复发和耐药患者的生活质量,改善患者预后提供了一种方法。对IPHC的药物代谢动力学及其在晚期及复发与耐药卵巢癌中的可行性、有效性、安全性进行综述。
Most ovarian cancer patients have been diagnosed late clinical stage, although after the ideal tumor cytoreductive surgery and cisplatin-based combination chemotherapy, there are still some patients relapse, resistance. Therefore, advanced ovarian cancer is still the leading cause of death in current female reproductive system malignancies. Intraperitoneal hyperthermic chemotherapy (IPHC) is a promising treatment for improving the quality of life, improving the prognosis of patients with advanced, recurrent and resistant patients. The pharmacokinetics of IPHC and its feasibility, efficacy and safety in advanced and recurrent and drug resistant ovarian cancer were reviewed.